Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) COO Sells 233 Shares of Stock

Key Points

• COO Mark Jacobson sold 233 shares at an average price of $228.18 for about $53,165.94, reducing his stake by 4.91% to 4,517 shares (roughly $1.03M).
• Q1 results missed expectations: GAAP EPS was -$1.26 vs. a -$0.85 consensus, though revenue rose ~57% YoY to $191.2M, driven by AUVELITY and SUNOSI, leaving the company still unprofitable with negative margins and ROE.
• Shares traded down modestly to $223.06 on higher-than-average volume while several analysts raised price targets and coverage, leaving a consensus rating of Moderate Buy with an average target around $251.89.

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark Jacobson sold 233 shares of the company's stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $228.18, for a total value of $53,165.94. Following the completion of the transaction, the chief operating officer owned 4,517 shares in the company, valued at $1,030,689.06. This represents a 4.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Axsome Therapeutics Stock Down 0.3%

Shares of AXSM traded down $0.64 during trading hours on Tuesday, reaching $223.06. The company's stock had a trading volume of 1,019,532 shares, compared to its average volume of 882,597. The firm has a market cap of $11.47 billion, a price-to-earnings ratio of -59.80 and a beta of 0.59. Axsome Therapeutics, Inc. has a 1-year low of $96.09 and a 1-year high of $234.29. The company has a quick ratio of 1.48, a current ratio of 1.55 and a debt-to-equity ratio of 1.38. The company has a 50 day moving average of $171.73 and a two-hundred day moving average of $163.34.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.41). The business had revenue of $191.20 million during the quarter, compared to analyst estimates of $191.10 million. Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 246.90%. The company's revenue for the quarter was up 57.4% on a year-over-year basis. As a group, research analysts predict that Axsome Therapeutics, Inc. will post -1.05 EPS for the current fiscal year.

Analyst Ratings Changes

AXSM has been the subject of several recent research reports. TD Cowen reissued a "buy" rating on shares of Axsome Therapeutics in a research note on Friday. Wolfe Research initiated coverage on Axsome Therapeutics in a research note on Monday, February 23rd. They issued an "outperform" rating and a $230.00 price target for the company. Royal Bank Of Canada boosted their price target on Axsome Therapeutics from $242.00 to $302.00 and gave the company an "outperform" rating in a research note on Tuesday. Oppenheimer set a $280.00 price target on Axsome Therapeutics in a research note on Monday. Finally, Jefferies Financial Group boosted their price target on Axsome Therapeutics from $245.00 to $275.00 and gave the company a "buy" rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Axsome Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $251.89.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Very strong top-line growth — 1Q net product revenue of $191.2M, up ~57% YoY, driven by AUVELITY ($153.2M) and SUNOSI ($33.9M); this validates commercial traction for Axsome’s lead products. Axsome 1Q 2026 Financial Results
• Positive Sentiment: Multiple analyst price-target lifts today (notably Mizuho to $310, Wells Fargo to $255, Baird to $246, Morgan Stanley to $242) and continued “buy/outperform” coverage increase perceived upside and support near-term sentiment. Analyst Coverage & Price Target Moves
• Positive Sentiment: Pipeline and corporate catalysts remain in play — AUVELITY approval for agitation in Alzheimer’s, NDA submission for AXS‑12 (cataplexy), addition of AXS‑20 to the pipeline — these can drive medium/long-term upside. Business Update & Pipeline Highlights
• Neutral Sentiment: Management outreach: Axsome will participate in multiple investor conferences (BofA fireside chat, others) — useful for additional disclosure but timing/impact is uncertain. Investor Conference Participation
• Neutral Sentiment: Full earnings and call transcripts are available for deeper read-throughs; analysts and commentators are parsing sequential trends and guidance in detail. Earnings Call Transcript & Analysis
• Negative Sentiment: Earnings miss: GAAP EPS of ($1.26) vs. consensus (~$0.85 loss) — the wider loss and negative margins/ROE raise near-term profitability concerns despite revenue strength. Q1 Loss Widens; Revenues Jump (Zacks)
• Negative Sentiment: Some skepticism on sustainability — commentary notes sequential sales dips for key products and questions about achievability of management’s long‑term peak revenue targets, which could temper enthusiasm. Earnings Review & Skepticism (Seeking Alpha)

Institutional Investors Weigh In On Axsome Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Illinois Municipal Retirement Fund bought a new stake in Axsome Therapeutics during the first quarter worth approximately $884,000. Hillsdale Investment Management Inc. bought a new stake in Axsome Therapeutics during the first quarter worth approximately $9,019,000. Fifth Third Bancorp boosted its position in Axsome Therapeutics by 554.6% during the first quarter. Fifth Third Bancorp now owns 16,214 shares of the company's stock worth $2,741,000 after purchasing an additional 13,737 shares during the period. Hsbc Holdings PLC bought a new stake in Axsome Therapeutics during the first quarter worth approximately $11,589,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in Axsome Therapeutics by 6.8% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,030 shares of the company's stock worth $343,000 after purchasing an additional 130 shares during the period. Institutional investors own 81.49% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.